The outcomes of favipiravir exposure in pregnancy: a case series.

Creative Commons License

Ertem O., Guner O., Incir C., Kalkan S., Gelal A.

Archives of gynecology and obstetrics, no.1, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.1007/s00404-022-06615-z
  • Journal Name: Archives of gynecology and obstetrics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, MEDLINE
  • Keywords: Favipiravir, Pregnancy outcomes, Teratogen
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose As in vitro and in vivo studies reported antiviral efficacy against RNA viruses, favipiravir, a pyrazinecarboxamide derivative, has become one of the treatment options for COVID-19 in some countries including Turkey. Preclinical studies demonstrated the risk for teratogenicity and embryotoxicity. Hence, the drug is contraindicated during pregnancy. Although limited in numbers, case-based evaluations indicate that favipiravir might not be a major teratogen in human pregnancies. This study aimed to present and analyze the outcomes of favipiravir exposure during pregnancy.